Literature DB >> 26841811

Comparison of the EORTC STO-22 and the FACT-Ga quality of life questionnaires for patients with gastric cancer.

Aaron Woo1, Terence Fu1, Marko Popovic1, Edward Chow2, David Cella3, C Shun Wong1, Henry Lam1, Natalie Pulenzas1, Breanne Lechner1, Sherlyn Vuong1, Vithusha Ganesh1, Andrew Bottomley4.   

Abstract

This review compares the development, characteristics, validity, and reliability of two well-known quality of life (QOL) assessment tools used in patients with gastric cancer: the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach (EORTC QLQ-STO22) and the Functional Assessment of Cancer Therapy-Gastric (FACT-Ga). A literature search was conducted using MEDLINE, EMBASE, and Cochrane CENTRAL (inception to April 2015) to identify studies that discussed the development, characteristics, validity and reliability of the EORTC QLQ-STO22 or the FACT-Ga. The QLQ-STO22 was developed with collaboration with patients, healthcare professionals and literature review and was mainly field tested in European countries. Conversely, items on the FACT-Ga were generated from interviews with patients and healthcare professionals concurrently in North America and Asia. While both modules involve a 7-day recall period and use Likert scales, the QLQ-STO22 and FACT-Ga differ in terms of QOL domain focus, quantity and presentation of items, response options, and scoring. However, both tools show good internal consistency, test-retest reliability, sensitivity to change and construct validity. In addition, both questionnaires have been internationally validated within a large sample of patients undergoing a variety of treatments, thus demonstrating their cross-cultural applicability. The EORTC QLQ-STO22 and FACT-Ga are both valid and reliable tools with unique strengths and weaknesses. Selection between instruments should consider specific patient characteristics and goals of the study.

Entities:  

Keywords:  European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Stomach (EORTC QLQ-STO22); Functional Assessment of Cancer Therapy-Gastric (FACT-Ga); Gastric cancer; quality of life (QOL); questionnaire

Mesh:

Year:  2016        PMID: 26841811     DOI: 10.3978/j.issn.2224-5820.2016.01.02

Source DB:  PubMed          Journal:  Ann Palliat Med        ISSN: 2224-5820


  5 in total

Review 1.  Quality of Life After Curative Resection for Gastric Cancer: Survey Metrics and Implications of Surgical Technique.

Authors:  Yinin Hu; Victor M Zaydfudim
Journal:  J Surg Res       Date:  2020-03-07       Impact factor: 2.192

2.  Symptom Evolution in Patients with Esophageal and Gastric Cancer Receiving Palliative Chemotherapy: A Population-Based Study.

Authors:  Shaila J Merchant; Weidong Kong; Michael Brundage; Christopher M Booth
Journal:  Ann Surg Oncol       Date:  2020-11-02       Impact factor: 5.344

3.  Quality of life as a fundamental outcome after curative intent gastrectomy for adenocarcinoma: lessons learned from patients.

Authors:  Rodrigo Nascimento Pinheiro; Samantha Mucci; Renato Morato Zanatto; Olavo Magalhães Picanço Junior; Augusto Angelo Granado Bottino; Renata Pereira Fontoura; Gaspar de Jesus Lopes Filho
Journal:  J Gastrointest Oncol       Date:  2019-10

4.  Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.

Authors:  Josep Tabernero; Maria Alsina; Kohei Shitara; Toshihiko Doi; Mikhail Dvorkin; Wasat Mansoor; Hendrik-Tobias Arkenau; Aliaksandr Prokharau; Michele Ghidini; Catia Faustino; Vera Gorbunova; Edvard Zhavrid; Kazuhiro Nishikawa; Takayuki Ando; Şuayib Yalçın; Eric Van Cutsem; Javier Sabater; Donia Skanji; Catherine Leger; Nadia Amellal; David H Ilson
Journal:  Gastric Cancer       Date:  2020-03-04       Impact factor: 7.370

Review 5.  Health-related quality of life after gastric cancer treatment in Brazil: Narrative review and reflections.

Authors:  Rodrigo Nascimento Pinheiro; Samantha Mucci; Renato Morato Zanatto; Olavo Magalhães Picanço Junior; Alexandre Ferreira Oliveira; Gaspar de Jesus Lopes Filho
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.